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INTRODUCTION 
           Hemophilia is a group of hereditary X-linked recessive disorder 
characterised by deficiency of factor VIII or IX coagulant activity. The 
pathophysiology of Hemophilia A and Hemophilia B is based on the 
insufficient generation of thrombin by the factor IXa/factor VIIIa complex 
through the intrinsic pathway of the coagulation cascade. [1] 
           It is the most common congenital bleeding disorder encountered in 
clinical practice affecting men, whereas females are usually carriers [2]. 
Depending on the level of factor activity, it is further classified as Mild (6-
40%), Moderate (1-5%) and Severe (<1%) [3]. 
           Bleeding can occur anywhere from the body. The common sites are into 
joints and muscles and from the gastrointestinal tract. Approximately 75 
percent of  hemorrhage occurs in the joints and is the hallmark of hemophilia 
[1]; the most commonly involved joints are the ankles, knees and elbows. These 
three joints are therefore referred to as Index joints. Spontaneous hemarthrosis 
are characteristic of severe disease. Recurrent bleeding into joints leads to 
extensive destruction of articular cartilage, synovial hyperplasia and reactive 
changes which then leads to joint deformity, muscle atrophy and soft tissue 
contractures, eventually leading to permanent joint damage. 
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           India has the second highest hemophilia burden in the world. Being a 
resource limited country where most of people with hemophilia are given only 
on-demand therapy, it is an utmost necessity to look into certain factors which 
could have influence over development of crippling arthropathy until 
prophylactic therapy which is the optimal therapy, is being made available to 
all people with hemophilia. 
           This study aims at evaluation of Hemophilic joint clinically, functionally 
and radiologically using Hemophilia Joint Health Score 2.1, Functional 
Independence Score in Hemophilia and Pettersson score respectively. 
            Hemophilia Joint Health Score 2.1(HJHS) is a clinical scoring to assess 
joint health, in the domain of body structure and function (i.e., impairment), of 
the joints most commonly affected.             
           Functional Independence Score in Hemophilia (FISH) is a performance-
based instrument used to objectively assess musculoskeletal function of 
patients with hemophilia. [4]. 
           The Pettersson score is a detailed radiologic classification of hemophilic 
joints that has been adopted by the World Federation of Hemophilia (WFH). It 
estimates joint destruction radiologically [5]. 
           These scoring tools are  simple, inexpensive, accessible, reproducible 
and several studies had shown minimal inter/intra-observer variability, hence 
could be used as a reference for further follow-up of patients which would help 
to improve the quality of life and thus aid in decreasing the significant 
morbidity which comes with the development of permanent joint damage. 
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AIMS OF THE STUDY 
 
• To assess pattern of joint involvement & the most common joint involved in 
hemophilia patients attending Govt. Royapettah hospital. 
• To assess target joint clinically using HEMOPHILIA JOINT HEALTH 
SCORE 2.1 
• To assess the functional activity of hemophilia patients using 
FUNCTIONAL INDEPENDENCE SCORING. 
• To assess radiological scoring of the joint using PETTERSSON’S SCORE. 
• Assessment of factors influencing hemophilic arthropathy.  
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REVIEW OF LITERATURE 
HISTORY OF HEMOPHILIA 
           Hemophilia is a rare X-linked coagulopathy. The earliest written 
references to what must have been human hemophilia date back to the 2nd 
century during the ruling of Rabbi the Patriarch when a Jewish woman’s third 
son is exempted from circumcision if his two elder brothers died of bleeding 
after circumcision. It was recorded by Talmud, a collection of Jewish 
rabbinical writings on laws and traditions. 
           In 1828, it was referred to as “haemorrhaphilia” which means Love of 
Bleeding. 
           In 1911, Addis recognised that the defect was correctable with a small 
amount of normal plasma but was attributed to the deficiency of prothrombin. 
Later in the 1930s and 1940s, with the advent of better purification techniques, 
the component of thrombokinase was identified. 
In the 19th century several authors recognised the link between bleeding 
episodes to the delayed blood coagulation. Morawitz developed the classical 
theory of coagulation that involved 2 reactions – 
1. Conversion of prothrombin to thrombin by a tissue substance, 
thrombokinase. 
2. Conversion of fibrinogen to fibrin by thrombin. [6] 
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           Brinkhous[7] identified that the basic defect was a delayed conversion of 
prothrombin to thrombin which he corrected by adding a small fraction of 
plasma containing anti-hemophilic factor later named as factor VIII. In 1952, 
Aggeler and his co-workers described the deficiency in patient of ‘plasma 
thromboplastin component’ different from factor VIII which was later named 
as factor IX. 
EPIDEMIOLOGY 
           Hemophilia occurs in all ethnic groups [8]. International incidence of 
Hemophilia is found to be 1 in 5000 to 7000 live male births.50to 60 percent of 
patients have severe, 25 to 30 percent have moderate and 15 to 20 percent have 
mild hemophilia. The annual incidence of Hemophilia A has been estimated at 
approximately 1: 5000 male births. The incidence of Hemophilia B is estimated 
at approximately 1: 30,000 male births [8]. 
Between 2009 and 2010, 260[9], [10] new patients were reported from 
India while there were 1,38,41,667[11] male births. This implies that the 
incidence was around 2 per 1,00,000 male births. If the incidence of 20 per 
1,00,000 is used, the number of new cases in 2010 would be 2768. 
A survey conducted by World Federation of Hemophilia in 2011 
included 108 countries and covered 90.6 percent of global population [12]. In 
India, disease registry for hemophilia is available with Hemophilia Federation 
of India (HFI) [13] that collects data through 76 centres located across India. The 
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data showed that India reported 14,718 patients with bleeding disorder and 
11,586 patients with haemophilia A[12].  
           The USA and Brazil reported highest prevalence of over 4 per 1,00,000 
population while prevalence in India is 0.9 per 1,00,000 population which 
could be due to under-diagnosis, mortality and incomplete case reporting. 
Adjusting the under-diagnosis in India to the prevalence rate in USA, the 
estimated number of patients with Hemophilia A would be around 54,454 and 
that of Hemophilia B around 21,931. 
 
Fig 1: Global distribution of total reported cases of bleeding disorders (a) and hemophilia A (c) in five 
countries reporting the highest number of patients. (b) and (d) show that nearly 5 and 9% of global 
patients with bleeding disorders and hemophilia A are from India. (Source: Authors’ calculation based 
on data fron Ref.29) 
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FUTURE PLANS IN INDIA 
 
 
           India lacks a proper surveillance system. With the data obtained from 
other developed countries that have an established surveillance system, the 
magnitude of cases in our country can be estimated. India could have around 
70,000 patients as estimated from the prevalence data of USA. This large case 
load might be due to the improving medical services or due to the increased life 
span of these patients. 
           With the expected high case load, the need for a national programme for 
Hemophilia must be emphasized. The problem of equity should be kept in 
mind. People from the lower socio economic status and rural areas must be 
made accessible to the factor products. Compulsory Hepatitis B vaccination 
must be emphasized. Routine screening for HIV and HCV should be done for 
persons with Hemophilia. 
           The data on epidemiology and the cost incurred in treating a patient is 
lacking in our country. However, data regarding the genetic basis of the disease 
and the prenatal diagnosis is available. Pre-natal diagnosis is carried out in a 
few premier institutes within the country. 
           Maintaining a Hemophilia registry is important in order to obtain 
information regarding the disease burden and trends in our country. 
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ETIOLOGY 
Hemophilia A and B are heterogenous X-linked recessive disorders 
occurring due to a mutation in either the coagulation factor VIII gene or factor 
IX gene. Hemophilia A results from the reduced levels of functional factor VIII 
in the peripheral circulation which can be due either to decreased levels or 
decreased functionality of factor VIII [1]. 
Factor VIII must be activated by thrombin for it to be an effective 
cofactor of factor IXa. The capacity of Factor IXa to activate Factor X 
exponentially is increased in the presence of activated factor VIII - FVIIIa. 
Thus the clinical manifestations of Hemophilia A and B are clinically 
indistinguishable from each other. Together Factor IXa and VIIIa activate 
factor X which is necessary for effective thrombin formation. In the absence of 
either of the coagulation factors clot formation is delayed and the clot thus 
formed is easily friable, dislodged and subjected to fibrinolysis which leads to 
excessive bleeding. 
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GENETICS [8] 
 
Hemophilia A and B are X linked recessive disorders. About 30% of 
Hemophilia A mutations can arise de-novo. The gene for Factor VIII is large 
with 26 exons and 25 intervening introns. This makes identification of the 
mutation difficult. 
 
All the sons of affected hemophiliac males are normal while all the 
daughters are obligatory carriers. Sons of carriers have 50% chance of being 
affected and the daughters of the carriers have a 50% chance of being carriers 
themselves. In female carriers, because of lyonization there might be 
preferential expression of the defective hemophilic allele. Such females who 
have Hemophilia are called “lyonized carriers”. Other mechanisms for female 
Hemophilia include homozygosity for the defective Factor VIII allele and 
hemizygosity for the defective gene. 
No single mutation can cause Hemophilia. Hundreds of deletions, point 
mutations and inversions have been identified. 
Analysis of Factor IX mutations show that it occurs due to endogenous 
processes – deamination of CpG dinucleotides rather than from environmental 
effects. As with Hemophilia A, no single gene has been attributed to the 
development of Hemophilia B. 
 
 
13 
 
FACTOR VIII GENE AND HEMOPHILIA: 
 
Factor VIII gene contains 186 kb with 26 exons, and produces an 
mRNA transcript of 9kb which is translated into 2351 amino acid polypeptide. 
The mature protein is divided into homologous domains named A1, A2, B, A3, 
C1,C3.                    
          The most common defect is inversion of 500-600 kb region that results in 
disruption of F8 region of intron 22. Additional inversion of Intron 1 of Factor 
VIII contributes to 5% of severe Hemophilia[14]. Point mutations involving 
CpG dinucleotide are more common. 
 
 
Fig 2: Structure of Factor VIII gene. 
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FACTOR IX GENE AND HEMOPHILIA B [15]: 
 
           The gene for factor IX is located on the long arm of chromosome X. It is 
much smaller than the gene for factor VIII measuring only around 33kb. 
F9 is the gene’s official symbol. The F9 gene is located on the long (q) arm of 
the X chromosome between positions 27.1 and 27.2.[14] 
 
 
 
 
Fig 3: Structure of Factor IX gene 
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INHERITANCE PATTERN OF HEMOPHILIA 
Mother is a carrier: 
-50% chance that each son will have hemophilia 
-50% chance that each daughter will be a carrier of the gene. 
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Father has Hemophilia: 
-All daughters will carry the hemophilia gene. 
-No sons will have hemophilia. 
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Father has Hemophilia and Mother is a carrier: 
-50% chance that each son will have hemophilia. 
-50% chance that each daughter will be a carrier of the gene. 
-50% chance that each daughter will have hemophilia. 
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THE CLOTTING CASCADE 
1. VASCULAR CONSTRICTION 
2. PLATELET ACTIVATION 
3. EXTRINSIC PATHWAY 
4. INTRINSIC PATHWAY 
5. FINAL COMMON PATHWAY 
6. COFACTORS 
7. REGULATORS 
 
Fig 4: The coagulation cascade 
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VASCULAR CONSTRICTION: 
           After trauma, the blood vessel responds immediately by vasoconstriction 
which prevents further bleeding. This is mediated by local myogenic reflex, 
local autocoid factors released by the vessel wall, platelets and neurogenic 
reflex of which the myogenic reflex is the most powerful. The neurogenic 
reflex originates from  pain nerve endings. Thromboxane A2 is the most 
important vasoconstrictor. 
 
PLATELET ACTIVATION: 
         The next step in the clotting cascade is platelet activation. Small cuts 
can be sealed by platelet plug itself without activation of coagulation cascade. 
The platelet cell membrane has a glycoprotein that normally repulses 
attachment to the vessel wall but gets attached to injured endothelium and 
exposed collagen. In addition, platelet contains phospholipids that activate 
various stages of coagulation process. 
           When platelets comes in contact with collagen they swell up and release 
their granules with the help contractile proteins like actin, myosin and 
thrombasthenin, which makes them more sticky and bind avidly to each other 
and to the exposed collagen and Von Willebrand factor. It also releases ADP 
which forms Thromboxane A2. This process leads to formation of platelet 
plugs which seals the injured blood vessel. 
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COAGULATION CASCADE: 
The coagulation process is initiated by three factors [1] [8] 
 Damage to vessel 
 Damage to the blood components 
 Exposure of blood to damaged endothelial cells or the underlying 
collagen 
In each instance, it leads to the formation of the prothrombin activator 
which converts prothrombin to thrombin. 
The prothrombin activator can be formed by two processes:- 
 EXTRINSIC PATHWAY – Begins with the trauma to the vessel wall. 
 INTRINSIC PATHWAY – Begins in the blood itself. 
 
EXTRINSIC PATHWAY [1]: 
           This is also known as tissue factor pathway. This begins with the 
exposure of blood to the damaged extra-vascular tissue or traumatised vessel 
wall. 
 
STEPS: 
1. Release of TISSUE FACTOR: Damaged vessel releases several tissues 
factors or tissue thromboplastin.  
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2. FACTOR VII AND TISSUE FACTOR: The lipoprotein tissue factor 
forms complexes with Factor VII and in the presence of Calcium 
catalyses the activation of Factor X to Xa. 
3.  Factor Xa combines with Factor V and in the presence of calcium 
becomes the PROTHROMBIN ACTIVATOR. 
4.  Prothrombin activator complex in the presence of calcium converts 
prothrombin to thrombin and the coagulation continues. 
     In the prothrombin activator complex, Factor X is the actual protease 
and Factor V accelerates the protease activity. The formed thrombin further 
activates Factor V which becomes an additional accelerator of prothrombin 
activator thereby becoming a positive feedback mechanism.  
 
 
 
 
 
Fig 5: Extrinsic pathway of coagulation 
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INTRINSIC PATHWAY [1] 
The second pathway for initiating coagulation is the intrinsic pathway 
which gets activate with damage to the blood components.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
               Fig 6: Intrinsic pathway of coagulation 
 
 
STEPS: 
1. Trauma to blood causes activation of Factor XII. There is formation of a 
primary complex on collagen by high molecular weight kininogen, 
prekallikrein and Factor XII. Prekallikrein is converted to kallikrein and 
factor XII to a protease – Factor XIIa. 
2. Factor XIIa activates Factor XI to XIa.  
3. The activated Factor XI then enzymatically cleaves Factor IX to form 
the activated Factor IXa. 
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4. The activated Factor IXa, along with activated factor VIIIa, Platelet 
factor 3 and platelet phospholipids end in activating Factor X to Xa. 
Factor VIII is also known as the anti-hemophilic factor. 
5. This step is the same as in intrinsic pathway. The activated Factor X 
combines with Factor V to form the prothrombin activator complex. 
6. The prothrombin activator causes conversion of prothrombin to 
thrombin thereby setting the coagulation cascade into motion. 
 
FINAL COMMON PATHWAY: 
 
1) CONVERSION OF PROTHROMIN TO THROMBIN: 
            Prothrombin activator formed either by the intrinsic or extrinsic 
pathway converts prothrombin to thrombin in the presence of ionic calcium. 
Thrombin causes polymerization of fibrin molecules within 10-15 seconds. 
Platelets also play a role in the formation of thrombin as most of the 
prothrombin binds to their receptors present on the surface of platelets. The rate 
limiting step in coagulation process is the formation of the prothrombin 
activator. 
           Prothrombin is formed by the liver and needs Vitamin K for its 
formation. So, in the presence of liver failure or vitamin K deficiency, 
production is grossly impaired and can result in coagulopathy. 
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2) CONVERSION OF FIBRINOGEN TO FIBRIN AND CLOT 
FORMATION: 
 
            Thrombin is a multifunctional enzyme. It converts soluble plasma 
fibrinogen to an insoluble fibrin matrix and a resultant clot formation. 
Fibrinogen is a high molecular protein, (MW=3,40,000), produced in the liver. 
            Within a few minutes after clot formation, it begins to contract. 
Platelets contribute to the process of clot retraction. The contractile process 
within the platelets gets activated and this is involved in clot retraction. The 
contraction is activated by thrombin and accelerated by calcium released from 
the endoplasmic reticulum and Golgi apparatus within the platelets. It also 
releases pro-coagulant factors. As the clot retracts, the edges of injured vessels 
are pulled together thereby leading to complete hemostasis. 
 
COFACTORS: 
 
 CALCIUM: 
          Except for the first two steps of the intrinsic pathway, calcium ions are 
needed for the activation and propagation of the entire coagulation cascade. 
The levels of ionised calcium rarely become low enough to affect the 
coagulation. But after sampling, addition of citrate binds with the ionised 
calcium or oxalate, which precipitates the calcium. 
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 VITAMIN K: 
           Vitamin K is essential for the gamma carboxylation of Factor II, VII, IX 
and X, the process essential for the factors to bind to phospholipids and thereby 
participate in the coagulation cascade. In the absence of vitamin K, either due 
to deficiency or liver disease, defective proteins PIVKAs (Proteins formed in 
the absence of Vitamin K) are formed that do not contribute effectively to the 
coagulation cascade. 
 
 
REGULATORS [8] 
     There are four mechanisms that keep platelet activation and the 
coagulation cascade in check. Abnormalities can lead to an increased tendency 
toward thrombosis: 
 Protein C  
Protein C is activated into Activated protein C (APC) by Thrombin. 
APC inhibits factor Va and VIIIa. This causes termination of the role of 
factor VIIIa in the tenase complex and that of factor Va in forming the 
prothrombin activator complex. The net effect on the coagulation 
cascade is inhibition of further fibrin and there by clot formation.  
 Antithrombin is a serine protease that inhibits factor Xa and thrombin. 
Antithrombin deficiency can cause thrombotic disorders. 
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 Tissue factor pathway inhibitor (TFPI) limits the action of tissue 
factor (TF) and also inhibits excessive TF-mediated activation of Factor 
VII and Factor X. 
 Plasmin is produced from plasminogen, a zymogen produced in the 
liver. Plasminogen after binding to clots adopts an open conformation 
and can be activated to plasmin by a variety of factors, the most 
important of which is Tissue plasminogen activator. Plasmin deficiency 
is rare in humans. 
 
PRENATAL DIAGNOSIS AND CARRIER DETECTION 
[14] [16] 
Prenatal diagnosis can be suggested to woman those who are related to 
obligate Hemophilia carriers and known Hemophiliacs. Germ line mutations 
have different implications when it occurs in the grandfather and the mother. 
Prenatal diagnosis can performed in the eleventh to twelfth week of 
gestation either by amniocentesis or chorionic villous sampling. If the foetus is 
a female little is the concern as carrier females rarely have bleeding 
manifestations. In case of a male foetus, the diagnosis can be made by DNA 
analysis of the cells.  
Studies identified the causative mutation in 90% of patients with mild 
and moderate hemophilia A but only 50 to 60% of patients with severe disease 
[16].  
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CLINICAL PRESENTATION [1] [17] [18] 
           Clinical presentation of Hemophilia A and B are indistinguishable. 
 Severe hemophilia (factor level less than 1 percent of normal) tends to 
present in early infancy with spontaneous hemorrhage. 
 Moderate hemophilia (factor level 1-5 percent of normal) may present 
with increased bleeding after minor trauma or surgery. Spontaneous 
bleeding is rare. 
 Mild hemophilia (factor level 6-40 percent of normal) bleeds secondary 
to surgery. Spontaneous bleeding is rare. 
 Most carriers have factor level more than 50 percent and do not have 
bleeding manifestation. 
 
INTRAPARTUM COMPLICATIONS 
A study of the modes of delivery and peri-natal complications in 
affected male babies shows that the risk of intracranial bleed is less in normal 
delivery. (<3.8%)[19]. The risk of sub-galeal and cephalic hematoma increases 
with vacuum delivery. Forceps delivery and prolonged labour increase the risk 
of intracranial bleeds. Caesarean section does not eliminate the risk. Seizures 
are common during the acute intracranial bleed episode. 
Psychomotor complications and cerebral palsy can occur as long term 
complications. In a European study, involving 508 children born with 
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Hemophilia A or B, intracranial bleeds occurred in 18 (3.5%) within the first 
28 days of life [19]. 
 
CIRCUMCISION AND BLEEDING 
About half of undiagnosed hemophilic patients develop excessive 
bleeding during circumcision. Failure to bleed does not eliminate the presence 
of Hemophilia in that patient [1]. 
 
 
AGE OF BLEED ONSET 
Children with severe hemophilia become symptomatic within the first 2 
years of life. In a study, the mean age of first bleed leading to the diagnosis was 
at 0.9 years of age, in the absence of any prothrombotic factor coinheritance. 
The mean age for diagnosis was around 1.6 years of age in the presence of 
prothrombotic factors [7]. Joint bleeds are very common and early diagnosis 
would help to prevent the joints from hemarthropathy. 
The age of diagnosis in mild and moderate hemophilia is later than that 
for severe hemophilia. About one third of mild hemophilia have very few 
bleeding episodes which may go undetected for a very long period of time. 
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HEMARTHROSIS [1] [8]: 
           Bleeding into joints accounts for about 75 percent of all bleeding events 
and is the hallmark of hemophilia[1]. The most commonly involved joints are 
the ankles, knees and elbow, referred to as index joints. Shoulder, hips and 
wrist are less commonly involved. Least involved are joints of the hands and 
feet. 
           Synovium has numerous cells and abundant capillaries. These capillaries 
are susceptible to damage during mechanical trauma leading to joint bleed. 
Hemarthroses might produce an aura of discomfort that gradually progresses to 
cause joint enlargement and excruciating pain. The joint becomes swollen, 
warm and tender interfering with range of movement. The pain    subsides in 6 
to 8 hours once bleeding stops and disappears in 12 to 18 hours. The blood is 
reabsorbed in a couple of days. However, repeated bleeding causes articular 
destruction with resultant hemophilic arthropathy. The synovium then becomes 
thickened and folded and is more prone for repeated bleed with lesser pain as 
compared to bleed into a normal synovium. 
          The presence of fever, leukocytosis and other systemic manifestations 
suggests the probability of an infected hemarthroses. Rapid diagnosis is a must 
as infection in such joint progresses rapidly causing loss of joint space and 
architecture. The joint should be aspirated and factor replacement should be 
given. Chronic hemophilic arthropathy is painful with weight bearing but the 
pain subsides or disappears once the joints become ankylosed. Muscle atrophy 
30 
 
around the joint can lead to increased inability and increased bleeding from the 
loss of cushioning effect provided by the muscles. 
           Patients with factor levels greater than 20% of normal rarely develop 
hemophilic arthropathy even if they have experienced previous bleeds [8]. Socio 
economic status and other health effects have an influence on the morbidity of 
hemophilic arthropathy. 
 
Radiographic stages of hemophilic joint [8]: 
 
Fig 5: Radiographic stages of hemophilic joint. 
Stage 0 – Normal joint 
Stage 1 – fluid in the joint 
Stage 2 – Osteoporosis and epiphyseal overgrowth – Fig A 
Stage 3 – Subchondral bone cysts – Fig B (arrowheads) 
Stage 4 – Prominent bone cysts with marked narrowing of joint space – Fig C 
(arrows) 
Stage 5 – Joint obliteration with epiphyseal overgrowth 
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HEMATOMAS 
Hematomas can occur in the subcutaneous plane or into the muscle [8]. 
They are very characteristic of clotting factor deficiencies. Hematomas with 
bleeding into the muscles occur most commonly in the quadriceps, iliopsoas 
and forearm. 
Retroperitoneal hematomas can dissect through the diaphragm into the 
chest and neck and compromise the airways. They might cause ureteral 
obstruction and compromise renal function. An abdominal hematoma can 
rupture and drain into the colon which is very rare and most often fatal. 
Iliopsoas bleeds tend to be large and compromise neurovascular 
structures causing compartment syndrome. These bleeds can be localised with 
ultrasound and require larger doses of factor VIII [20]. 
Patients with Hemophilia can develop hematoma of the bowel wall and 
present as appendicitis, intestinal obstruction or intussusceptions.  
 
PSEUDOTUMOR  
Pseudotumor is also known as blood cysts. There are three types [8], 
Type 1: Simple cyst; confined by the tendinous attachment within the 
fascial muscle. 
Type 2: Simple cyst that compromises the vascular supply to the 
adjacent bone and periosteum resulting in bone resorption and cyst formation. 
Type 3: Subperiosteal bleeding resulting in separation of the periosteum 
from the bone cortex. 
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Pseudotumors contain either a serosanguinous fluid or brownish 
material surrounded by a fibrous membrane. Pain is due to either rapid 
collection or compression of nearby neurological structures. It tends to expand 
over years and can become multi-loculated. Sinus tract maybe formed which is 
a risk factor for infection. 
Most common sites are in the lower limb but can occur at other sites.  
MRI and CT help in diagnosis. Needle biopsy should be avoided for fear 
of bleeding and infection. The only definitive treatment is complete excision. It 
tends to reform if incompletely removed. 
 
HEMATURIA 
Hematuria is frequently seen in severe hemophiliacs. Bleeding can occur 
from anywhere along the genitourinary tract. It may be associated with trauma 
but most often is spontaneous, episodic and usually painless. Although rare, 
renal calculi must be ruled out. 
 
NEUROLOGICAL COMPLICATIONS 
Intracranial bleed is the most severe hemorrhagic event. It is the leading 
cause of death in both neonates and children with hemophilia. It is also the 
leading cause of morbidity in children due to its long term consequence like 
seizure, mental retardation, motor dysfunction [1]. It may occur spontaneously 
but most commonly after a trivial trauma. Suspicion of an ICH should arise 
when a known person with hemophilia complains of severe headache. 
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           Bleeding into the spinal cord is very rare and can result in paraplegia [21]. 
Epidural bleeding compressing the cord is more common. 
           Muscle hematomas can result in peripheral nerve compression of which 
femoral nerve compression by iliopsoas bleeds is most common and can result 
in sensory loss over the anterior and lateral thigh, weakness and atrophy of the 
quadriceps. Ulnar nerve is the next most commonly involved peripheral nerve. 
 
Fig 7: Intracranial hemorrhage in hemophilia           Fig 8: Ilio-psoas muscle 
 
 
MUCOUS MEMBRANE BLEEDS 
           Mucous membrane is common. It may present as epistaxis, oral 
bleeding, and peptic ulcer bleed disease. Occult blood loss in urine or stools 
might contribute to the iron deficiency. 
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POST SURGICAL BLEED 
           Dental extraction is the most common surgical procedure done on 
hemophilia patients. Mild or moderately hemophilia patients are at times 
diagnosed only after surgical procedures when bleeding cannot be controlled. 
Appropriate factor replacement can prevent intra operative and postoperative 
bleeding. 
 
COMPLICATIONS IN HEMOPHILIA 
       There are three major complications that can occur in persons with 
hemophilia. 
1. Joint destruction and abnormalities due to hemarthroses: Hemophilic 
Arthropathy. 
2. Blood borne infection  
3. Development of Inhibitor antibodies 
 
1. HEMOPHILIC ARTHROPATHY[1] 
There are several factors that contribute to the development of 
arthropathy, the most important of which would be the deposition of iron in the 
synovium and the development of synovial fibrosis that leads to contracture 
formation. These joints are more prone for further bleeding which would 
perpetuate the vicious cycle. It causes significant morbidity due to pain and 
limitation of range of motion of the joint affected. 
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Primary prophylactic treatment with factor VIII or IX dramatically 
reduced the incidence of arthropathy and increased the quality of life. A 
randomized control trial comparing three times per week prophylactic dosing 
against the on-demand dosing showed that prophylactic dosing was superior to 
on-demand dosing schedule. 
           The relative risk of MRI detected joint damage with episodic therapy as 
compared with prophylaxis was 6.1 (95% CI 1.5-24) [22]. Orthopedic 
complications still remain a major issue as on-demand treatment is still the 
treatment followed in India. 
The completed Joint Outcome Study in the United States demonstrated 
that prophylaxis with Factor VIII at 25-35 units per kilogram body weight 
every other day is superior to intensive on-demand (e.g., 40 units/kg initially, 
then 25 units/kg at 24 and 72 hours) factor replacement therapy in preventing 
joint disease in previously pristine joints at age six years. The 80 per cent lower 
incidence of pristine joints in the on-demand arm was confirmed by validated 
physical exam and radiographic scoring as well as by follow-up magnetic 
resonance imaging of ankles, knees, and elbows in the 66 children randomly 
assigned between the two arms of the study [19]. 
 
2. BLOOD-BORNE INFECTION 
           HIV, hepatitis C and intracranial hemorrhagic are the leading cause of 
death[1]. But with the advent of recombinant products, intensive donor 
screening and virucidal techniques, the incidence has dramatically reduced. 
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Since the mid 1980s, no HIV infection has been reported with the use of anti-
hemophilic factor. 
Other rare infections that can be transmitted through the use of anti-
haemophilic factors are parvo B19, Creutzfeldt Jacob disease and the new 
variant of CJD.  
 
3. DEVELOPMENT OF INHIBITORS 
           It is the most important complication among hemophilia patients treated 
with factor VIII or IX concentrate. 
           The development of inhibitors is more common with Hemophilia A than 
B. Hemophilia A phenotype is most commonly due to a null mutation thereby 
predisposing to the development of inhibitors. On the other hand, factor IX 
shares significant homology with other vitamin K-dependent clotting factors 
which could possibly protect against inhibitor development [1]. In severe disease 
30%, moderate disease 3% and in mild disease 0.3% tend to develop inhibitors 
[23]. 
Genetic and environmental factor also plays a role. There is a three-fold 
increase in risk with the presence of a first degree relative with Inhibitors. 
Inversion of intron 22, large deletions affecting more than one domain 
and nonsense mutations involving the light chain plays an important role.  
Inhibitor development is seen more in patients exposed to continuous 
factor infusions as seen during surgeries [1].  
 
37 
 
Table 1: Risk factors for development of Inhibitor 
 
 
 
HEMOPHILIA A & INHIBITORS 
Normally, when factor VIII is non-covalently bound to vWF via the 
light chain. Upon thrombin activation, factor VIIIa dissociates from VWF and 
via the C2 domain, which is no longer bound by VWF, binds to 
phosphatidylserine on the platelet membrane. Inhibitors interrupt this process 
through a number of different mechanisms. These antibodies belong to the 
IgG4 subclass.With the development of inhibitors, patient responds poorly to 
treatment and experience bleed more frequently. Any hemophilia patient who 
fails to respond to treatment should prompt the possibility of development of 
inhibitors. 
           The diagnosis is made by using the Bethesda assay. It was developed in 
1975 and it depends on the ability of the patient’s plasma to inactivate factor 
VIII in the normal plasma. The result is expressed in Bethesda units [15]. A mild 
modification of this is the Nijmegen assay. 
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DIAGNOSIS AND DETECTION OF CARRIERS 
Family history of bleeding especially on the maternal side should be 
sought for. The mother can be identified as a carrier when a family history of 
bleeding is present. However, the lack of family history does not rule out 
hemophilia as about one-third of patients have a negative family history.  
 
REASONS FOR NO FAMILY HISTORY 
 There might be spontaneous mutations involving factor VIII gene. 25 to 
33 % of cases are known to have spontaneous mutations [9]. 
 Negative family history as might happen if there are neonatal deaths or 
the passage of the trait through successive female carriers [9]. 
Symptomatic hemophilia is well documented in female. The possible reasons 
include, 
 Unequal and early inactivation of the X chromosome 
 Mating between an affected male and a carrier female produces 
homozygous disease in one half of the female offspring. 
 An abnormal karyotype as in Turner’s syndrome. 
SCREENING TESTS 
 Three initial tests should be performed in patients presenting with 
unknown bleeding disorder. 
1. Platelet count 
2. Prothrombin time 
39 
 
3. Activated partial thromboplastin time.            
           The characteristic laboratory finding in Hemophilia A and Hemophilia B 
are normal PT, Platelet count and a prolonged aPTT. The test is abnormal in 
those with factor levels less than 30%. As mild diseases may have normal 
aPTT, factor assays should be done in case of a mild undiagnosed bleeding 
disorder with normal laboratory values. 
Other disorders that prolong the aPTT but not the PT include: 
-Inherited: 
 Deficiency of factor XI, XII, prekallikrein, or HMW kininogen. 
 Von Willebrand disease. 
-Acquired: 
 Inhibitors of factor VIII,IX,XI or XII. 
 Acquired Von Willebrand disease, Lupus anticoagulant, Heparin 
administration. 
            In the absence of inhibitor, the elevated aPTT should be correctable 
with pooled normal plasma. 
 
SPECIFIC ASSAYS 
Specific assays for factor deficiency that result in isolated prolonged 
aPTT are done in the order of statistical significance – VIII, IX and XI.  
There are two methods to perform the assay – one stage method and two 
stage method. The one stage method is preferred as it easier and cheaper. 
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The principle of the test involves plotting clotting time against sample 
dilution. The degree of correction of the clotting time when the plasma is added 
to the clotting system specifically deficient in the clotting factor to be measured 
allows the level of that clotting factor to be determined. 
Other methods that have developed include Chromogenic substrate 
assay,  Immunoradiometric methods and Enzyme-linked immunosorbent assay. 
 
DIFFERENTIAL DIAGNOSIS 
 Von Willebrand disease 
 Platelet disorders – eg. Glanzmann thrombasthenia 
 Other clotting factor deficiency – V,VII,X or XI 
 Acquired hemophilia 
     Hemophilia is diagnosed in the presence of a positive family history, 
prolonged bleeding, hemarthroses and spontaneous soft tissue bleeds. The last 
two features differentiate it from von Willebrand disease in which 
hemarthroses and soft tissue bleeds are generally rare except in case of severe 
type 3 disease. 
     The main differentiating factors are a prolonged bleeding time, reduced 
von Willebrand antigen assay and abnormal ristocetin induced platelet 
aggregation. vWd – Normandy variant is difficult to distinguish from 
Hemophilia A. In the Normandy variant there is impairment in the 
incorporation of factor VIII into the von Willebrand factor. 
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     Differentiating Hemophilia A and B is impossible from history and 
physical examination. Factor assays are needed to differentiate between 
Hemophilia A and B and of other clotting factor deficiency. 
Acquired Hemophilia is also seen in autoimmune syndromes, in which 
inhibitors to Factor VIII develop spontaneously. 
 
TREATMENT 
It includes 
 Preventive measures 
 Treatment with factor replacement  
 Treatment of complications 
PREVENTIVE MEASURES: 
Circumcision 
Approximately 40% of undiagnosed hemophiliacs bleed in association 
with circumcision [1]. For this reason, male babies born to female carriers 
should be deferred from the procedure. Fibrin glue can be used to reduce the 
bleeding. 
 
Immunisation 
The routine immunizations can be given preferably subcutaneously [24]. 
If intramuscular is to given, it is best done soon after a dose of factor infusion 
and pressure and ice packs should be applied for five minutes at the injection 
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site. Hepatitis A and B immunization is important for all people with 
hemophilia. Live virus vaccine maybe contraindicated with co-infection with 
HIV. 
 
Dental Care 
Proper dental care should be advocated. The patients should be taught 
about the importance of routine cleaning and maintenance of oral hygiene. 
Early and proper toothbrush training should be given to the children. 
 
Counselling and Education 
Psychosocial counselling and social support should be given to the 
patient and their families [25][26]. Hemophilia is also a financial burden that 
places restrictions on several aspects of normal living [27]. Information 
regarding physical, psychological, emotional and economic dimensions of 
hemophilia should be provided and patients should be encouraged to engage in 
productive and leisure activities. 
 
Fitness and physical activity 
For fear of bleed, most of Hemophilia patients tend to become sedentary 
and end up with obesity which is a risk factor for increased bleed in the weight 
bearing joints. With the advent of prophylaxis all over the world, The World 
federation for Hemophilia advocates regular exercise regimen.  
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REPLACEMENT THERAPY 
Factor replacement therapy is the cornerstone to the management of 
Hemophilia. The dosing is standard but the length of the treatment; choice of 
product depends on individual decision.  
 
Table 2: Recommendations for Factor Replacement [1] 
Site of Bleed Level desired 
(%) 
Hemophilia A 
FVIII (U/kg) 
Hemophilia B 
FIX (U/kg) 
Oral mucosa >30 20 40 
Epistaxis  >30 20 40 
Joint / Muscle >50 30 50 
Gastro-intestinal >50 30 50 
Genito-urinary >50 50 75 
CNS* >100 75 125 
Trauma/Surgery >100 75 125 
*CNS-central nervous system 
 
                 The minimum factor level required for hemostasis has not been 
established.  
In the absence of inhibitor, each unit of FVIII or FIX per kilogram of 
bodyweight infused will raise the plasma factor level approximately by 2 IU/dl 
and 1 IU/dl respectively [27.] The decrease in factor level post transfusion 
depends on the pharmacokinetics of the factor. 
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Half-life of FVIII is 8 to 12 hours and that of FIX is 18-24 hours. 
Patients factor level should be measured approximately 15 minutes after 
infusion to verify calculated dose [27]. Half of the initial dose can be repeated 
every eight hours to maintain the desired factor level [28] [1]. 
Solvent treated fresh frozen plasma can be given in the absence of factor. 
 
1stGENERATION RECOMBINANT FACTOR VIII 
These recombinant factors are derived from the cell cultures of 
transfected hamster derived cell lines and need no further purification. The 
human albumin, added for stabilization purposes, contributes to the risk of viral 
contamination. 
 
2nd GENERATION RECOMBINANT FACTOR VIII 
This recombinant factor does not contain albumin. Instead, sucrose is 
added for stabilization. 
 
3rd GENERATION RECOMBINANT FACTOR VIII 
These have no added albumin or added protein at the end of preparation. 
 
INVESTIGATIONAL STRATEGIES 
A potentially exciting advance is to develop a product that would bind 
both Factor X and IXa, thereby bringing the two substrates together and 
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bypassing the cofactor function of Factor VIII. This interesting idea is still 
under study. 
The choice of product depends on the purity, safety and cost. Purity and 
viral safety are utmost important to both, the treating physician and the patient. 
Ultrapure products are preferred in patients co-infected with HIV as they 
stabilize the CD4 counts. 
 
FACTOR IX PRODUCTS 
In the 1970s and 80s, Prothrombin complex concentrate (PCC) produced 
by the co-purification of Vitamin K dependant cofactors was used. This co-
purification resulted in the activation of Factor VII to VIIa resulting in increase 
thrombotic complications and is no longer preferred for the same. Instead, 
purified human derived or recombinant factors are used. 
 
PURIFIED FACTOR IX 
Chromatographic partitioning and monoclonal antibody affinity 
purification are the techniques used to purify Factor IX. They are further 
subjected to viral inactivation processes. 
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RECOMBINANT FACTOR IX 
It is genetically engineered by inserting the gene for factor IX into a 
Chinese hamster ovary cell line. It has no added albumin and is safe in the 
treatment of patients with previously treated and untreated Hemophilia B.  
Half-life of recombinant factor is about 16 to 17 hours. 
 
LONGER ACTING PRODUCTS 
     Factor preparation with longer half-life is desirable as it would decrease 
the frequency of dosing intervals. The two strategies under study for 
prolonging the half-life of factor VIII/IX are 
 Fusion with the Fc portion of immunoglobulin. 
 Reconstitution with pegylated liposomes or albumin. 
 
 
HEMOPHILIA VIII & INHIBITORS 
 
HIGH RESPONDERS 
High responders are defined as patients whose inhibitor titre is higher 
than 10 Bethesda units (BU) at baseline or whose initial inhibitor titre is less 
than 10 BU but rises to greater than 10 BU after administration of factor VIII 
[29]. 
Major bleeding episodes in these groups can be treated with high doses of 
either human factor VIII or porcine Factor VIII, which will overcome the 
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inhibitors.    Although factor VIII bypass agents can be used, it is not as reliable 
and the effects cannot be monitored by a reliable blood investigation. 
In major bleeds factor VIII is given in a dose of 10,000 to 15,000 units 
stat followed by 1000 units per hour infusion with frequent monitoring of 
factor VIII levels[29][30]. 
In patients who experience minor bleeds, the preferred treatment would 
be factor VIII inhibitor bypass activity or Recombinant factor VIIa. The dose 
of Recombinant factor VIIa is 90 to 120mcg/kg that can be repeated at two to 
three hour intervals [30]. 
Patients with inhibitors >10BU rarely respond to high levels of factor 
VIII. The treatment of choice would be either recombinant factor VIIa or factor 
VIII inhibitors bypass activity for both minor and major bleeds. 
 
LOW RESPONDERS 
Low-responder patients are arbitrarily defined as patients whose 
inhibitor titre is less than 10 BU even after challenge with factor VIII. For 
major bleeds high dose of factor VIII is recommended. In case of minor bleed, 
recombinant factor VIIa or FEIBA is preferred as most low responders become 
high responders when challenged with repeated doses of factor VIII [30]. 
 
FACTOR IX AND INHIBITORS 
 When the inhibitor titre is less than 10BU, it can be overcome with high 
doses of factor IX. In case of acute bleeds in patients with inhibitor levels 5 
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to10 BU/ml should be treated with same factors used to bypass the activity of 
factor VIII inhibitor. Recombinant factor VIIa can be used in the dose of 90 to 
120 mcg/kg ever 2 to 3 hours [31]. Induction of immune tolerance can be tried 
with daily dosing of purified factor IX. 
 
IMMUNE TOLERANCE INDUCTION 
It is the most promising approach to the eradication of inhibitors. It 
involves daily exposure of these patients to factor VIII either by low dose or 
high dose regimens. Bleeds that happen during these periods are treated with 
factor VIII inhibitor bypass activity [1] [29]. 
           Other immunosuppressive drugs, including cyclosporine and Rituximab 
have been tried. However, they seem more promising in cases of acquired 
antibodies, in which case the antibodies are autoantibodies rather than 
alloantibodies as seen in Hemophilia patients. 
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Table 3: Immune tolerance induction 
 
 
OTHER TREATMENT OPTIONS IN HEMOPHILIA A 
 
DESMOPRESSIN 
Desmopressin is effective in mild to moderate hemophilia. The dose is 
0.3mcg/kg body weight and the factor level increases 30 to 60 minutes after 
infusion. A concentrated nasal spray can be used at a dose of 150mcg in each 
nostril [30]. Tachyphylaxis can happen with repeated administration. 
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ANTIFIBRINOLYTIC THERAPY 
Epsilon aminocaproic acid (EACA) and tranexamic acid can be used as 
adjuvant in cases of mucosal bleeds. They are contraindicated in the presence 
of hematuria. The dose of EACA is 4 to 5gms stat followed by 1gm/hr. 
Tranexamic acid can be given as 1g every fourth hourly [31] [1]. 
 
FIBRIN GLUE 
Also known as fibrin tissue adhesive, most commonly used as an 
adjunctive to dental procedures. It contains a mixture of fibrinogen, thrombin 
and factor XIII and can be applied topically to the injury site. 
 
LIVER TRANSPLANTATION AND GENE THERAPY 
         Liver transplantation has been done successfully in patients with 
Hemophilia and has been shown to result in complete cure.  
           Gene therapy is promising. After 2 decades of excellent progress, there 
is a hope that clinical success will be achievable [1]. 
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MATERIALS AND METHODS 
This study was done at Government Royapettah Hospital, Chennai for a 
period of Six months from April 2017 to September 2017. The study was 
performed after procuring informed written consent from all the participants 
involved. Clearance was obtained from the Ethical Committee of Government 
Kilpauk Medical College & Hospital Chennai. 
 
STUDY DESIGN 
           The study design is a cross sectional study. 
 
POPULATION 
The study population included 60 persons with hemophilia who attended 
the Hemophilia Clinic at Government Royapettah Hospital. 
 
INCLUSION CRITERIA 
Patients confirmed with Hemophilia including; 
   1. Factor VIII deficiency (factor viii assay <40% of normal) with joint 
involvement. 
   2. Factor IX deficiency (factor ix assay <40% of normal) with joint involvement. 
   3. Age group: 4-18 years. 
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EXCLUSION CRITERIA 
 
1. Children <4 years or >18 years. 
2. Patients with acute joint bleed or hemodyanamically unstable. 
3. Hemophilia A or B with bleed other than joint. 
4. Any bleeding disorders other than Hemophilia. 
5. Not given consent for the study. 
 
METHODOLOGY 
Persons with Hemophilia A or B presenting to Hemophilia clinic were 
assessed after obtaining written informed consent. The sample size was set to be 
60. Based on previous records and by obtaining history& physical examination, 
target joints were assessed using Hemophilia joint health score 2.1, functional 
scoring assessed as per FISH scoring system &conventional radiographs of the 
target joint taken and scores assigned using Pettersson’s score. A detailed 
questionnaire assessing various factors which could influence the scores was taken 
into account, and final association established between them.   
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FUNCTIONAL INDEPENDENCE SCORE IN HEMOPHILIA 
(FISH) [2] 
The Functional Independence Score in haemophilia (FISH) is a 
performance-based assessment tool to objectively measure an individual’s 
functional ability. It can also be used to evaluate change in functional 
independence over time. 
           The advantage is that it can be used with persons of different linguistic 
abilities, as it is an objective, performance-based instrument. It includes the 
assessment of 8 activities: eating, grooming, dressing, chair transfer, squatting, 
walking, step climbing, and running.  Each activity is graded according to the 
amount of assistance required to perform it.  
 
LEVELS OF FUNCTION AND THEIR SCORES 
4- The subject is able to perform the activity without any difficulty. 
3-The subject is able to perform the activity without aids or assistance, but 
with slight difficulty.  
2- The subject needs partial assistance/ aids/ modified instruments/ 
modified environment to perform the activity. 
1- The subject is unable to perform the activity, or needs complete 
assistance. 
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HEMOPHILIA JOINT HEALTH SCORE 2.1 
           In the 1980s, Petterson and Gilbert developed a scoring system for 
assessment of hemophilic arthropathy- the World federation of hemophilia (WFH) 
physical examination (PE) scale which was the most widely used instrument. 
However, with the development of prophylaxis it seems to lack sensitivity. In 
2003, the physiotherapy expert working group of International prophylaxis study 
group (IPSG) developed a more sensitive tool, the HJHS version 1.0, to evaluate 
and monitor effectiveness of treatment. In 2008, the HJHS version 2.1 was 
developed in which modifications in axial alignment, joint pain, gait and instability 
to the HJHS 1.0 were made. 
           The HJHS measures joint health in the domain of body structure and 
function of the joints. It is primarily designed for children aged 4-18years. It can 
be used when there is need for orthopaedic intervention or as outcome measure of 
physiotherapy intervention. 
           It is appropriate for use in both patients receiving prophylaxis and On-
demand therapy. 
           HJHS 2.1 is an 8 item scoring tool for assessing impairment of six index 
joint (ankle,knee,elbow). It is numerically scored from zero to 20 and global gait 
score of zero to 4. Score ranges from zero to 124 with higher scores being worst. 
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PETTERSSON SCORE 
           It is a detailed radiologic classification of hemophilic joint that was 
recommended by the Orthopedic Advisory Committee and has been adopted by 
the 
  World  Federation of Hemophilia. It estimates joint destruction radiologically.  
           In this scoring system, the extent of the arthropathy is estimated by 
following Eight characteristics:  
 OSTEOPOROSIS,  
 EPIPHYSEAL ENLARGEMENT, 
 NARROWING OF JOINT SPACE,  
 IRREGULARITY OF THE SUBCHONDRAL SURFACE,  
 EROSION AT JOINT MARGINS,  
 SUBCHONDRAL CYSTS,  
 JOINT INCONGRUENCY, AND  
 JOINT DEFORMITY.  
           In each item, a score of 0 to 2 is given. The sum of these score will give the 
joint score which may range from 0 to 13 points. 
          The concept of this system is to allow subtle grading of extent of pathology 
for the purpose of follow up. 
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STATISTICAL 
ANALYSIS 
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 The collected data were analysed with IBM.SPSS statistics software 
23.0 Version. To describe about the data descriptive statistics frequency 
analysis, percentage analysis were used for categorical variables and the mean 
& S.D were used for continuous variables. To find the significant difference 
between in the multivariate analysis the Kruskal Walli's test was used. To 
assess the relationship between the variables Spearman's rank Correlation was 
used. In both the above statistical tools the probability value 0.05 is considered 
as significant level.  
 
 
P –Value ** Highly Significant at P ≤0.01 
 
    P –
Value * Significant at 0.01 < P ≤ 0.05 
 
    P –
Value # No Significant at P >0.05 
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TABLE 4:TYPE OF DISEASE 
 
TYPE OF 
DISEASE Frequency Percent 
Valid 
Percent 
 
Cumulative Percent 
  
A 
 
55 
 
91.7 
 
91.7 
 
91.7 
      
 
B 
 
5 
 
8.3 
 
8.3 
 
100.0 
 
     
 
Total 
 
60 
 
100.0 
 
100.0 
 
 
 
Fig 9: Pie-chart showing frequency of Type of Hemophilia 
 
Out of 60 hemophilia patients, 92% were Hemophilia A;8% were 
Hemophilia B 
 
TYPE A
92%
TYPE B
8%
60 
 
TABLE 5: SEVERITY OF DISEASE 
 
 
Frequency Percent 
Valid 
Percent Cumulative Percent 
Valid 
 
 
 
Mild 
 
7 
 
11.7 
 
11.7 
 
11.7 
 
Moderate 
 
11 
 
18.3 
 
18.3 
 
30.0 
 
Severe 
 
42 
 
70.0 
 
70.0 
 
100.0 
 
Total 
 
60 
 
100.0 
 
100.0 
 
 
 
  Fig 10: Pie-chart showing frequency of severity of Hemophilia 
 
Out of 60 patients, majority (70%) were persons with Severe; 18% moderate 
and 12% mild Hemophilia. 
 
12%
18%
70%
Mild Moderate Severe
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*JT- JOINT; MM-MUCOUS MEMBRANE; MS-MUSCLE 
Fig 11: Pie-chart depicting the type of bleed experienced. 
 
Out of 60 patients, 42% had involvement of joint alone; 32% has joint and 
mucous membrane bleed; 23% had joint and muscle bleed; 3% had 
combination of joint, muscle and mucous membrane bleed.                 
  
JOINT
42%
JT + MM
32%
JT+MM+MS
3%
JT + MS
23%
 
TABLE 6:TYPE OF BLEED 
 
 
Frequency Percent 
Valid 
Percent Cumulative Percent 
Valid  
JOINT 
 
25 
 
41.7 
 
41.7 
 
41.7 
 
JT + 
MM 
 
19 
 
31.7 
 
31.7 
 
73.3 
 
JT + 
MM 
+ MS 
 
2 
 
3.3 
 
3.3 
 
76.7 
 
JT + MS 
 
14 
 
23.3 
 
23.3 
 
100.0 
 
Total 
 
60 
 
100.0 
 
100.0 
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TABLE 7:NUMBER  OF JOINT INVOLVED 
 
  
Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
 
 
Valid 
 
MULTIPLE 
 
28 
 
46.7 
 
46.7 
 
46.7 
 
 
SINGLE 
 
32 
 
53.3 
 
53.3 
 
100.0 
 
 
Total 
 
60 
 
100.0 
 
100.0 
 
 
                   
Fig 12: Pie-chart showing number of joint involved. 
 
Out of 60 patients, 53% had single joint; 47% had multiple joint involvement. 
 
 
 
 
47%
53%
MULTIPLE SINGLE
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TABLE 8: PHYSIOTHERAPY 
 
  
Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
 
 
Valid 
 
OCCASIONAL 
 
25 
 
41.7 
 
41.7 
 
41.7 
 
 
REGULAR 
 
35 
 
58.3 
 
58.3 
 
100.0 
 
 
Total 
 
60 
 
100.0 
 
100.0 
 
 
 
Fig 13: Doughnut diagram showing frequency of physiotherapy 
 
 
Out of 60 patients, 58% were doing regular physiotherapy while 42% were 
doing occasionally. 
 
 
42%
58%
OCCASIONAL REGULAR
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TABLE 9: JOINT AFFECTED 
 
  
Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
 
 
Valid 
 
ANKLE 
 
24 
 
40.0 
 
40.0 
 
40.0 
 
 
ELBOW 
 
11 
 
18.3 
 
18.3 
 
58.3 
 
 
KNEE 
 
22 
 
36.7 
 
36.7 
 
95.0 
 
 
WRIST 
 
3 
 
5.0 
 
5.0 
 
100.0 
 
 
Total 
 
60 
 
100.0 
 
100.0 
 
 
 
Fig 14: Pie-chart showing the joints commonly affected. 
 
Out of 60 patients, there was involvement of ankle joint in 40%; knee joint in 
37%; elbow joint in 18%; wrist joint in 5%. 
 
 
40%
18%
37%
5%
ANKLE ELBOW KNEE WRIST
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Fig 15: Bar diagram showing the distribution of Target joint. 
 
The above diagram showed that patients can develop more than one target 
joint. Ankle was the most common target joint. 
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TABLE 10: DESCRIPTIVE STATISTICS 
 
  N Mean 
Std. 
Deviation Minimum Maximum 
 
 
AGE AT HEMARTHROSIS 
 
Mild 
 
7 
 
4.4857 
 
1.62832 
 
2.40 
 
7.00 
 
Moderate 11 2.4636 .81520 1.00 4.00 
 
Severe 42 1.4598 1.12038 .81 8.00 
 
Total 60 1.9968 1.49515 .81 8.00 
 
Avg. BLEED/Yr Mild 7 6.00 0.000 6 6 
 
Moderate 11 8.73 2.054 6 12 
 
Severe 42 12.02 3.204 6 18 
 
Total 60 10.72 3.528 6 18 
 
SELF CARE(TOTAL-12) Mild 7 12.00 0.000 12 12 
 
Moderate 11 11.91 .302 11 12 
 
Severe 42 11.24 1.144 8 12 
 
Total 60 11.45 1.016 8 12 
 
TRANSFER(TOTAL-8) Mild 7 7.29 1.254 5 8 
 
Moderate 11 7.18 .751 6 8 
 
Severe 42 6.74 .989 4 8 
 
Total 60 6.88 .993 4 8 
 
LOCOMOTION(TOTAL-12) Mild 7 10.29 1.254 8 12 
 
Moderate 11 10.73 1.104 9 12 
 
Severe 42 10.10 1.031 8 12 
 
Total 60 10.23 1.079 8 12 
 
FISH TOTAL(32) Mild 7 29.57 2.225 25 32 
 
Moderate 11 29.82 1.601 26 31 
 
Severe 42 28.12 1.811 24 31 
 
Total 60 28.60 1.942 24 32 
 
HJHS(0-124) Mild 7 9.43 4.756 5 16 
 
Moderate 11 11.18 7.068 4 27 
 
Severe 42 15.98 7.363 4 32 
 
Total 60 14.33 7.421 4 32 
 
GLOBAL GAIT Mild 7 1.29 .488 1 2 
 
Moderate 11 1.18 .603 0 2 
 
Severe 42 1.48 .890 0 3 
 
Total 60 1.40 .807 0 3 
 
PETTERSSON Mild 7 4.86 .900 4 6 
 
 
Moderate 
 
11 
 
6.00 
 
1.897 
 
3 
 
9 
 
 
Severe 
 
42 
 
7.12 
 
2.461 
 
2 
 
11 
 
 
Total 
 
60 
 
6.65 
 
2.349 
 
2 
 
11 
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Fig 16: Bar diagram showing Age of hemarthrosis in relation to severity of disease. 
 
The mean age of first hemarthrosis in severe disease was 1.4years (ranges from 
8 months to 8years). It was 2.4years and 4.4years in Moderate and Mild disease 
respectively. This shows that as factor activity decreases, there is earlier onset 
of first hemarthrosis. 
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      Fig 17: Bar diagram showing average bleed experienced in relation to severity of disease. 
 
The mean average number of bleed experienced per year was 12 (ranges from 6 
to 18 times) in severe disease. It was 9 and 6 in Moderate and Mild disease 
respectively. This shows that those with severe disease experienced more 
number of joint bleed as compared to moderate and severe group.  
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Fig 18: Bar diagram showing FISH score among study groups. 
 
The mean Functional Independence Score in Severe form of disease was 
28.12(ranges from 24 to 31). The mean score in Moderate and Mild disease 
were 29.82 and 29.57 respectively. The maximum score was 32 and was found 
in patient with Mild disease; minimum score was 24 and was found in Severe 
disease. 
 
 
 
27.00
27.50
28.00
28.50
29.00
29.50
30.00
Mild Moderate Severe
FISH 
70 
 
 
 
Fig 19: Bar diagram showing HJHS among study group. 
 
The mean HJHS was 16 (ranges from 4 to 32) in those with severe form of 
disease. It was 11 and 9 in those with Moderate and Mild form of disease 
respectively. The clinical joint health score was higher in group with severe 
disease which means that with severity of factor deficiency, the joint health 
declines. 
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        Fig 20: Bar diagram showing Global gait score. 
 
The mean Global gait score was 1.48 (ranges from 0 to 3) in patients with 
severe disease while in those with Moderate and Mild disease were 1.18 and 
1.29 respectively. This shows that with severity of the disease Global gait score 
also increase which they will have more impairment in their gait parameters 
namely walking, climbing stairs, running and hopping on one leg. 
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Fig 21: Scatter diagram depicting correlation of Pettersson score  
with Age of hemarthrosis. 
 
 
Fig 22: Correlation of Pettersson score with Average bleed per year. 
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Fig 23: Correlation of Pettersson score with HJHS 2.1 
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          The above table shows test statistics in patients with severe hemophilia. 
           The age at hemarthrosis and average bleed per year showed a strong 
statistically significant correlation with severity of the disease, that is, the age 
at first hemarthrosis is lower as the factor level declines and they experienced 
more bleed as compared to moderate and mild disease. 
           The three scoring system namely, FISH, HJHS 2.1 and Pettersson 
scoring also showed statistically significant correlation with severity, among 
which FISH showed the strongest correlation (p value 0.005). 
           On the other hand, even though Global gait score showed a higher score 
(higher score being worst) in those with severe disease, it is has not shown to 
be statistically significant (p value >0.05). 
 
TABLE 11: TEST STATISTICS IN PATIENTS WITH SEVERE HEMOPHILIA 
 
  Chi-Square df Asymp. Sig. 
 
AGE AT HEMARTHROSIS 
 
27.915 
 
2 
 
0.0005 
 
Avg. BLEED/Yr 
 
24.381 
 
2 
 
0.0005 
 
FISH TOTAL 
 
10.743 
 
2 
 
0.005 
 
HJHS 
 
8.698 
 
2 
 
0.013 
 
GLOBAL GAIT 
 
1.170 
 
2 
 
0.557 
 
PETTERSSON 
 
6.606 
 
2 
 
0.037 
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TABLE 12: CORRELATIONS 
 
  
Avg. 
BLEED/Yr 
FISH 
TOTAL HJHS PETTERSSON 
GLOBAL 
GAIT 
 Spearman's 
rho 
AGE AT 
HEMARTHROSIS 
Correlation 
Coefficient 
-.343** .128 -.172 -.105 .079 
 Sig. (2-
tailed) 
0.0005 0.329 0.190 0.423 0.549 
 N 60 60 60 60 60 
 
 
       Avg. BLEED/Yr Correlation 
Coefficient 
  -.637** .678** .679** .556** 
 Sig. (2-
tailed) 
  0.0005 0.0005 0.0005 0.0005 
 N   60 60 60 60 
 
 
       FISH TOTAL Correlation 
Coefficient 
    -.755** -.647** -.605** 
 Sig. (2-
tailed) 
    0.0005 0.0005 0.0005 
 N    60 60 60 
 
 
 
       
HJHS Correlation 
Coefficient 
      .649** .720** 
 Sig. (2-
tailed) 
      0.0005 0.0005 
 N       60 60 
 
 
 
      
PETTERSSON Correlation 
Coefficient 
        0.629** 
 Sig. (2-
tailed) 
        0.0005 
 N         60 
   
          There is a statistically significant correlation (p value <0.05) between 
each of the three scoring system and with that of average bleed per year; but 
not with that of the age of hemarthrosis. 
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DISCUSSION 
 
           The main cause of morbidity in patients with hemophilia is hemophilic 
arthropathy which is the consequence of repeated bleeding into the joints. The 
diseased joint is more prone for repeated bleeding which perpetuate the vicious 
cycle of joint bleed and further destruction of joint, hence arthropathy. 
           This study was carried out to evaluate hemophilic joint clinically, 
functionally and radiologically using Hemophilic joint health score 2.1(HJHS 
2.1), Functional independence score (FISH) and Pettersson score respectively. 
           In this study, Hemophilia A comprised of majority of cases (91.7%); 
42% had factor activity level <1% of normal. Up to 47% had multiple joint 
involvements. 
           The most commonly affected joint was Ankle in 40% of cases, Knee in 
37%, Elbow in 18.3%, Wrist in 5% which is in agreement with that of Jansen et 
al.[32] and Abdel Ghany et al[33], who found that the 3 large joints namely ankle, 
knee and elbow were the most common joint affected . A study done by Plug et 
al.[34], Aznar et al.[35] and Molho et al[36] also found the ankle to be the most 
common affected joint. In children, knee and ankle are weight bearing joint, 
hence bleed more often. On the other hand, wrist and elbow may be affected in 
infants when they start crawling as they became weight bearing joint in these 
age group. Shoulders and hips tend to bleed less due to better support [37]. 
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           The age at first hemarthrosis and average number of bleed per year 
shows statistical significance when compared with severity of disease, which 
means patients with lower factor activity has lower age of first joint bleed and 
increase in number of joint bleed per year. Similar result was seen in a study 
done by Abdel Ghany et al [33]. 
           The mean age of first hemarthrosis in severe hemophilia was 1.45 ±1.12 
years and range from 0.8 to 8 years. Pollmann et al [38] report that in nearly half 
of children with severe hemophilia, age of hemarthrosis occurs during first year 
of life. Fisher et al[39] added that 90% of youngster with severe hemophilia 
experience atleast one joint bleed before 4.5years of age. 
           The average bleed per year was also significantly increased in patients 
with severe hemophilia as compared to mild and moderate hemophilia. 
           Range of motion (ROM) has been the most utilised measurement for 
evaluating effects of intervention on joint health [40]. ROM limitation increases 
significantly with more episodes of joint bleed [41]. 
           In this study, FISH was significantly lower in patients with severe form 
of disease.  
           HJHS 2.1 also showed significant positive correlation with severity of 
the disease and average bleed per year. Global gait score was also higher with 
higher number of bleeds. 
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           Hassan et al [42] reported a significant positive correlation of Pettersson 
score with severity of disease. In our study showed similar results. Also, the 
average bleed per year showed a significant correlation which is in accordance 
with Van Dijk et al [43]. Fisher et al[39] reported that Pettersson score increases 
by 1 point for every 3 joint bleed occurring after 5 years of age. 
           Table.12 showed that the three scoring system namely FISH, HJHS 2.1, 
Pettersson score showed a statistically significant correlation with the average 
joint bleed per year but not with the age at hemarthrosis. On the contrary, the 
preceding table (Table 11) showed that there was a significant correlation with 
severe disease of age at hemarthrosis and the 3 scoring systems. So, the 
possible explanation for there not being a statistically significant correlation 
between age of hemarthrosis with the same 3 scoring systems could be due to 
those proportion with moderate and mild form of disease who seldom 
experienced spontaneous joint bleed, hence, lesser bleed in contrast to severe 
disease where bleeding is usually spontaneous.  
           Further, there is a significant positive correlation between the two 
scoring system namely, HJHS 2.1 and Pettersson score which is in accordance 
with a study done by P.M.Poonnoose et al [44]. On the other hand, both showed 
significant negative correlation with FISH. 
           Out of 60 patients, majority (58%) does regular physiotherapy, but its 
correlation with joint health was not been established. Perhaps in the future, the 
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effect of physiotherapy on joint health could be assessed and stressed on its 
importance. 
           All patients in the current study received On-demand therapy due to 
which they experience increase in number of bleeds per year and thus develop 
more degenerative changes within the joint affecting their functioning and 
quality of life. This was supported by previous studies [45] [46]. 
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CONCLUSION 
 
           In our study, a significant impairment of joint was demonstrated on the 
basis of severity of hemophilia using clinical, functional and radiological 
scoring system. Majority of our patients were having severe form of the disease 
(factor activity <1% of normal). The most common joint involved were ankle, 
knee and elbow. All of our patients received On-demand therapy which is 
inferior to prophylaxis but is the practised method of therapy in our country. 
           Scoring system namely FISH, HJHS 2.1, Pettersson proved to be useful 
tool for assessing joint health in persons with hemophilia. It can be used for 
follow up of patients to assess their response to treatment. Although MRI of 
joint is the preferred method for radiological assessment, in a poor resource 
country like India, Pettersson score using simple X-ray of the joint can be 
considered as a cost-effective alternative. 
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RECOMMENDATIONS 
           As previously mentioned, our country harbours the second highest 
hemophilia patients in the world, we need to initiate measures to make 
available to all, prophylactic factor therapy, which is the Ideal treatment, so as 
to improve the joint health, hence quality of life for hemophilia patients and 
help them live a near-normal life. 
           We also need to create more number of Hemophilia clinic throughout 
the country, as transport to hemophilia clinic during bleeding episode is 
cumbersome and helpless situation for both the patient and their care-givers. 
Also, as the patient continues to bleed till he reaches the nearest clinic where 
factor concentrates given and bleeding controlled, it therefore is a significant 
factor contributing to worsening of joint health. 
           Lastly, there is a need to initiate a National programme with the aim to 
improve surveillance, provide care, education, support for patients as well as 
their family and perhaps prevention through genetic counselling. 
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LIMITATIONS  
OF THE STUDY 
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LIMITATIONS OF THE STUDY 
          The test used some provocative movements which could not be done by 
some patients. Combination of FISH and HJHS takes long time to administer, 
approximately 60 minutes for each patient. There was exposure to patient of 
radiation for the purpose of Pettersson scoring of the joint, but was minimal. 
The scoring systems were objective, so the possibility of inter-observer 
variations cannot be dismissed. This study, unlike some does not allot the study 
population into sub-group for comparison hence, the age at which the patients 
start showing increased trend of disability was not assessed. Since, it was a 
cross-sectional study; there is no follow-up of the patients. Larger multicentre 
trials with more number of subjects are required. 
         
 
 
 
  
87 
 
 
 
 
BIBLIOGRAPHY 
 
  
88 
 
BIBLIOGRAPHY 
 
1. Hoffman textbook of Hematology. 
2. Scott JP, Montgomery RR. Hemorrhagic and thrombotic disorder. In: 
Kliegman RM, Behrman RE, Jenson BF, editors. Nelson's Text Book of 
Pediatrics. 18 th ed., Vol. 20. Philadelphia: Saunder; 2010. p. 61-88. 
3. Tantawy AAG. Molecular genetics of haemophilia-A:clinical 
perspectives. Egypt J Med Hum Genet 2010; 11 :105-114. 
4. Poonnoose PM, Thomas R, Bhattacharjee S, Shyamkumar NK, 
Manigandan C, Srivastava A. Functional Independence Score in 
Haemophilia (FISH): A new performance based instrument to measure 
disability. Haemophilia 2005; 11:598-602. 
5. Pettersson H, Ahlberg A, Nilsson IM. A radiologic classification of 
hemophilic arthropathy. Clin Orthop Relat Res 1980; 149:153–153159. 
6. Morawitz P: Die Chemie der Blutgerinnung. ErgebPhysiol 4:307, 1905 
7. Brinkhous KM: A study of the clotting defect in hemophilia. The 
delayed formation of thrombin. Am J Med Sci 198:509, 1939. 
8. Williams text book of haematology. 
9. World Federation of Hemophilia. Report on the Annual Global Survey 
2010. Montreal, QC, Canada: World Federation of Hemophilia; 2011.  
10. World Federation of Hemophilia (WFH). Report on the Annual Global 
Survey 2009. Canada: WFH; 2011.  
89 
 
11.  Census of India 2011, Office of the Registrar General and Census 
Commissioner, India, Controller of Publications, New Delhi. 
12. World Federation of Hemophilia (WFH). Report on the Annual Global 
Survey 2011. Canada: WFH; 2013.  
13.  KAR a, Phadnis S, Dharmarajan S, Nakade J. Epidemiology & social 
costs of haemophilia in India. Indian J Med Res 2014. 
14. Report of an expert workshop held at the Rockefeller Foundation Study 
and Conference Centre; 2005 April 14-20; Bellagio, Italy. 
15.  Kasper CK, Aledort L, Aronson D, et al: Proceedings: A more uniform 
measurement of factor VIII inhibitors.  ThrombDiathHaemorrh  1975; 
34:612. 
16. Medical genetics in developing countries. Annu Rev Genomics Hum 
Genet 2004; 5 : 219-65.Genome-based Research and Population Health. 
17. The aging patient with hemophilia: complications, comorbidities, and 
management issues. Hematology Am SocHematolEduc Program 2010; 
2010 : 191-6. Cohen JS, Biesecker BB.  
18. Quality of life in rare genetic conditions: a systematic review of the 
literature. Am J Med Genet A 2010;152A : 1136-56. Dharmarajan S, 
Phadnis S, Gund P, Kar A.  
19. Clinical features and manifestations of Haemophilia A – up-to-date. 
20. Gilbert MS: Musculoskeletal complications of haemophilia: The joint. 
Haemophilia 6:34, 2000. [PMID: 10982265] 
90 
 
21. Hanley JP, Ludlam CA: Central and peripheral nervous system 
bleeding, in Hemophilia, edited by CD Forbes, L Aledort, R Madhok, p 
87. Chapman & Hall, London, 1997. 
22. Steven MM, Yogarajah S, Madhok SD, et al: Hemophilic arthritis.  Q J 
Med  1986; 58:181 
23. Astermark J, Oldenburg J, Escobar M, White 2nd GC, Berntorp E: The 
Malmo International Brother Study (MIBS). Genetic defects and 
inhibitor development in siblings with severe hemophilia A.  
Haematologica  2005; 90:924. 
24.  Miller, E. J., Lee, C. A., Holmes, S., Kernoff, P. B. A., Thomas, H. C. 
and Karayiannis, P. (1989), Immune response of patients with 
congenital coagulation disorders to hepatitis b vaccine: Suboptimal 
response and human immunodeficiency virus infection. J. Med. Virol., 
28: 96–100. 
25. Cassis F. Psychosocial care for people with haemophilia. Treatment of 
Hemophilia monograph no 44. Montreal: World Federation of 
Hemophilia,2007. 
26. MILLER, R. (1999) Counselling about diagnosis and inheritance 
of genetic bleeding disorders: haemophilia A and B. Haemophilia, 
5: 77–83. 
27.  Björkman, S. & Berntorp, E. Pharmacokinetics of coagulation 
factors:clinical relevance for patients with haemophilia. Clin 
Pharmacokinet 2001;40(11:815-32). 
91 
 
28.  Factors affecting the Haemophilia Joint Health Scorein children with 
severe haemophiliaM. BLADEN, E. MAIN et al. 
29.  Astermark J, Oldenburg J, Escobar M, White 2nd GC, Berntorp E: The 
Malmo International Brother Study (MIBS). Genetic defects and 
inhibitor development in siblings with severe hemophilia A.  
Haematologica  2005; 90:924. 
30. Astermark J: Treatment of the bleeding inhibitor patient.  
SeminThrombHemost  2003; 29:77. 
31.  Hay CR, Baglin TP, Collins PW, Hill FG, Keeling DM: The diagnosis 
and management of factor VIII and IX inhibitors: A guideline from the 
UK Haemophilia Centre Doctors' Organization (UKHCDO).  Br J 
Haematol  2000; 111:78. 
32.  Jansen NW, Roosendaal G, Lafeber FP. Understanding haemophilic 
arthropathy: an exploration of current open issues. Br J Haematol 2008; 
143: 632–640. 
33.  Abdel Ghany HM, Hassab HM, El-Noueam KI. Hemophilic 
arthropathy: clinical, radiologic, and functional evaluation: a single-
center experience in a limited resource country. Egypt Rheumatol 
Rehabil 2016;43:35-4  
34. Plug I, van der Bom JG, Peters M et al. Thirty years of haemophilia 
treatment in the Netherlands, 1972-2001. Blood 2004; 104:3494-500. 
35. Aznar JA, Magallon M, Querol F, Gorina E, Tussel JM. The orthopaedic 
status of severe haemophiliacs in Spain. Haemophilia 2000; 6:170-6. 
92 
 
36. Molho P, Rolland N, Lebrun T et al. Epidemiological survey of the 
orthopaedic status of severe haemophilia A and B patients in France. 
The French Study Group secretariat.haemophiles@cch.ap-hop-paris.fr. 
Haemophilia 2000; 6:23-32. 
37.  Stephensen D, Tait RC, Brodie N, Collins P, Cheal R, Keeling D, et al. 
Changing patterns of bleeding in patients with severe haemophilia A. 
Haemophilia 2009; 15:1210–1214  
38. Pollmann H, Richter H, Ringkamp H, Jurgens H. When are children 
diagnosed as having severe haemophilia and when do they start to 
bleed? A 10-year single-centre PUP study. Eur J Pediatr 1999; 
158(Suppl 3):S166–S166S170. 
39.  Fischer K, van der Bom JG, Mauser-Bunschoten EP, Roosendaal G, 
Prejs R, de Kleijn P, et al. The effects of postponing prophylactic 
treatment on long-term outcome in patients with severe hemophilia. 
Blood 2002; 99:2337–2341. 
40.  Raffini L, Manno C. Modern management of haemophilic arthropathy. 
Br J Haematol 2007; 136:777–787. 
41.  Soucie JM, Cianfrini C, Janco RL, Kulkarni R, Hambleton J, Evatt B, et 
al. Joint range-of-motion limitations among young males with 
hemophilia: prevalence and risk factors. Blood 2004; 103:2467–2473. 
42. Hassan TH, Badr MA, El-Gerby KM. Correlation between 
musculoskeletal function and radiological joint scores in haemophilia A 
adolescents. Haemophilia 2011; 17:920–925. 
93 
 
43.  Van Dijk K, Fischer K, van der Bom JG, Grobbee DE, van den Berg 
HM. Variability in clinical phenotype of severe haemophilia: the role of 
the first joint bleed. Haemophilia 2005; 11:438–443. 
44. Poonnoose, P. M., Hilliard, P., Doria, A. S., Keshava, S. N., Gibikote, 
S., Kavitha, M. L., Feldman, B. M., Blanchette, V. and Srivastava, A. 
(2016), Correlating clinical and radiological assessment of joints in 
haemophilia: results of a cross sectional study. Haemophilia, 22: 925–
933. doi:10.1111/hae.13023 
45. Hassan TH, Badr MA, El-Gerby KM. Correlation between 
musculoskeletal function and radiological joint scores in haemophilia A 
adolescents. Haemophilia 2011; 17:920–925. 
46. Tlacuilo-Parra A, Villela-Rodriguez J, Garibaldi-Covarrubias R, Soto- 
Padilla J, Orozco-Alcala J. Functional independence score in 
hemophilia: a cross-sectional study assessment of Mexican children. 
Pediatr Blood Cancer 2010; 54:394–397. 
 
 
 
 
 
 
 
 
 
94 
 
 
 
 
 
ANNEXURES 
 
 
 
 
 
 
 
 
 
 
95 
 
ETHICS COMMITTEE CLEARANCE CERTIFICATE  
 
 
 
 
 
96 
 
 
 
 
PLAGIARISM CERTIFICATE 
97 
 
MASTER CHART 
SL. 
NO 
NAME AGE SEX 
TYPE OF 
DISEASE 
SEVERITY 
AGE AT 
HEMARTHROSIS 
TYPE 
OF 
BLEED 
NO. OF JT. 
INVOLVED 
Jt. 1st  
AFFECTED 
Avg. 
BLEED/Yr 
TARGET Jt. 
Type of 
Rx 
PHYSIO 
SELF 
CARE 
TRANSFER LOCOMOTION FISH HJHS 
GLOBAL 
GAIT 
PETTERSSON 
1 VARUN 8 M A SEVERE 1 YEAR JOINT SINGLE ANKLE 10 ANKLE 
ON 
DEMAND 
REGULAR 12 7 10 29 8 1 A(5) 
2 ABDUL 16 M A SEVERE 1.6 YEARS 
JT + 
MS 
MULTIPLE KNEE 14 
KNEE + ANKLE 
+ HIP 
ON 
DEMAND 
OCCASIONAL 12 4 8 24 28 2 
K(10) A(6) 
H(2) 
3 ADWAITH 7 M A SEVERE 2.5 YEAR 
JT + 
MS 
SINGLE ANKLE 12 ANKLE 
ON 
DEMAND 
REGULAR 12 8 10 30 8 1 A(2) 
4 MADHAN 17 M B MILD 7 YEARS JOINT MULTIPLE KNEE 6 KNEE + ANKLE 
ON 
DEMAND 
OCCASIONAL 12 5 8 25 16 2 K(6) A (4) 
5 KANNAN 15 M A MILD 4YEARS 
JT + 
MM 
SINGLE KNEE 6 KNEE 
ON 
DEMAND 
OCCASIONAL 12 6 11 29 10 1 K(4) 
6 AZRUDEEN 18 M A SEVERE 2 YEARS 
JT + 
MM 
MULTIPLE KNEE 12 
KNEE + ANKLE 
+ WRIST 
ON 
DEMAND 
REGULAR 10 5 9 24 27 3 
K(10) A(6) 
W(5) 
7 SADDAM 18 M A SEVERE 1.2 YEARS 
JT 
+MS 
MULTIPLE KNEE 16 
KNEE + 
SHOULDER + 
ELBOW 
ON 
DEMAND 
OCCASIONAL 9 6 10 25 32 1 
K(11) S(4) 
E(6) 
8 AKRAM 16 M A MILD 4YEARS 
JT + 
MS 
MULTIPLE KNEE 6 KNEE + ANKLE 
ON 
DEMAND 
REGULAR 12 8 10 30 16 2 K(4) A(3) 
9 BALAJI 17 M A SEVERE 1YEAR 
JT + 
MM 
MULTIPLE ANKLE 14 
WRIST + 
ANKLE + 
ELBOW 
ON 
DEMAND 
REGULAR 8 8 10 28 13 1 
W(6) A(4) 
E(7) 
10 SELVA 10 M A SEVERE 1YEAR 
JT + 
MS 
MULTIPLE ELBOW 14 
ELBOW + 
ANKLE 
ON 
DEMAND 
OCCASIONAL 9 8 10 27 24 1 E(11) A(5) 
11 VIGNESH 12 M A MODERATE 3YEARS JOINT MULTIPLE ELBOW 10 
ELBOW + 
ANKLE + KNEE 
ON 
DEMAND 
OCCASIONAL 11 6 9 26 27 2 
E(6) A(4) 
K(9) 
12 KARTHICK 14 M A SEVERE 2YEARS 
JT + 
MS 
MULTIPLE KNEE 16 KNEE + ANKLE 
ON 
DEMAND 
OCCASIONAL 12 5 8 25 26 3 K(6) A(10) 
13 RAJESH 17 M A MODERATE 4 YEARS JOINT SINGLE ANKLE 8 ANKLE 
ON 
DEMAND 
REGULAR 12 8 9 29 11 2 A(8) 
14 VIJAYAHAR 11 M A SEVERE 1 YEAR 
JT + 
MM 
MULTIPLE ELBOW 12 KNEE + ELBOW 
ON 
DEMAND 
REGULAR 11 7 10 28 20 2 K(8) E(4) 
15 DIYVESH 4 M B MODERATE 3 YEARS 
JT + 
MS 
SINGLE ANKLE 8 ANKLE 
ON 
DEMAND 
REGULAR 12 8 11 31 5 0 A(3) 
16 ANURUTH 13 M A SEVERE 11MONTHS 
JT + 
MS 
MULTIPLE WRIST 16 WRIST + KNEE 
ON 
DEMAND 
OCCASIONAL 10 6 9 25 12 2 K(8) W(6) 
17 KUMARAN 9 M A SEVERE 1YEAR 
JT + 
MM 
MULTIPLE ANKLE 14 B/L ANKLE 
ON 
DEMAND 
OCCASIONAL 12 6 10 28 22 2 A(8) A(6) 
18 VIJAY 18 M A MILD 6 YEARS 
JT + 
MS 
SINGLE ANKLE 6 ANKLE 
ON 
DEMAND 
REGULAR 12 8 10 30 6 1 A(6) 
19 ABISHEK 14 M A MODERATE 3 YEARS JOINT SINGLE ANKLE 8 ANKLE 
ON 
DEMAND 
REGULAR 12 8 11 31 8 1 A(6) 
20 YUVARAJ 13 M B SEVERE 1 YEAR 
JT + 
MS + 
MM 
MULTIPLE ELBOW 18 
ELBOW + 
ANKLE + HIP 
ON 
DEMAND 
OCCASIONAL 11 6 10 27 24 3 
E(6) A(10) 
H(4) 
21 KALVANARA 14 M A MILD 5 YEARS JOINT SINGLE KNEE 6 KNEE 
ON 
DEMAND 
OCCASIONAL 12 8 11 31 6 1 K(5) 
22 VENKATRAMAN 16 M A SEVERE 1 YEAR JOINT MULTIPLE ELBOW 16 ELBOW + KNEE 
ON 
DEMAND 
REGULAR 11 7 10 28 20 2 E(8) K(8) 
23 KUMAR 12 M A SEVERE 1 YEAR 
JT + 
MS 
SINGLE ANKLE 12 ANKLE 
ON 
DEMAND 
REGULAR 12 8 10 30 12 1 A(7) 
24 SASIKUMAR 18 M B MODERATE 1 YEAR 
JT + 
MS 
SINGLE ANKLE 12 ANKLE 
ON 
DEMAND 
OCCASIONAL 12 7 10 29 10 1 A(7) 
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25 NIRMAL 16 M A SEVERE 1 YEAR JOINT MULTIPLE KNEE 16 KNEE + ANKLE 
ON 
DEMAND 
REGULAR 12 7 9 28 26 3 K(11) A(4) 
26 SELVAM 15 M A SEVERE 1.5YEARS 
JT + 
MM 
MULTIPLE KNEE 18 KNEE + ANKLE 
ON 
DEMAND 
REGULAR 12 7 10 29 27 3 K(10) A(9) 
27 ANTHONY 4 M A SEVERE 2 YEARS 
JT + 
MS 
SINGLE ANKLE 8 ANKLE 
ON 
DEMAND 
REGULAR 12 7 11 30 8 1 A(4) 
28 S. BALAJI 6 M A SEVERE 1 YEAR 
JT + 
MM 
SINGLE ELBOW 8 ELBOW 
ON 
DEMAND 
REGULAR 8 8 12 28 4 NE E(5) 
29 SRIRAM 14 M A SEVERE 2YEARS JOINT MULTIPLE KNEE 14 KNEE + ANKLE 
ON 
DEMAND 
OCCASIONAL 12 6 9 27 27 3 K(10) A(6) 
30 PRAKASH 18 M A MODERATE 3 YEARS JOINT MULTIPLE KNEE 10 KNEE + ANKLE 
ON 
DEMAND 
REGULAR 12 7 10 29 21 2 K(6) A(4) 
31 SUNDAR 10 M A SEVERE 11MONTHS 
JT + 
MM + 
MS 
MULTIPLE ELBOW 10 ELBOW+ANKLE 
ON 
DEMAND 
OCCASIONAL 11 7 10 28 26 2 E(4) A(10) 
32 S. YUVARAJ 7 M A SEVERE 1 YEAR JOINT SINGLE KNEE 8 KNEE 
ON 
DEMAND 
REGULAR 12 7 11 30 8 1 K(8) 
33 GOVINDHAN 13 M A SEVERE 1.5 YEARS 
JT + 
MM 
SINGLE KNEE 11 KNEE 
ON 
DEMAND 
REGULAR 12 6 9 27 12 2 K(9) 
34 SRISHAN 16 M A SEVERE 8 MONTHS 
JT + 
MM 
MULTIPLE ELBOW 18 ELBOW +KNEE 
ON 
DEMAND 
OCCASIONAL 10 6 10 26 24 2 E(8) K(8) 
35 RAVIKUMAR 12 M A SEVERE 1 YEAR JOINT SINGLE ANKLE 12 ANKLE 
ON 
DEMAND 
REGULAR 12 8 10 30 10 1 A(6) 
36 KISHORE 10 M B MILD 3 YEARS JOINT SINGLE ANKLE 6 ANKLE 
ON 
DEMAND 
REGULAR 12 8 10 30 7 1 A(4) 
37 ANTHONY 9 M A SEVERE 1 YEAR 
JT + 
MM 
MULTIPLE KNEE 10 KNEE + ANKLE 
ON 
DEMAND 
REGULAR 12 7 11 30 14 2 K(6) A(2) 
38 SENTHIL 8 M A SEVERE 1.5YEARS 
JT + 
MM 
MULTIPLE ANKLE 8 
ANKLE + 
ELBOW 
ON 
DEMAND 
OCCASIONAL 11 7 11 29 12 1 W(2) E(4) 
39 VIJAY 10 M A MODERATE 2 YEARS 
JT + 
MM 
SINGLE KNEE 8 KNEE 
ON 
DEMAND 
REGULAR 12 6 11 29 13 1 K(8) 
40 WILSON 14 M A SEVERE 2.1 YEARS JOINT SINGLE KNEE 12 KNEE 
ON 
DEMAND 
REGULAR 12 6 10 28 14 1 K(8) 
41 ANNAVARAD 13 M A SEVERE 1.2 YEARS 
JT + 
MM 
MULTIPLE KNEE 12 KNEE + ANKLE 
ON 
DEMAND 
REGULAR 12 6 9 27 16 2 K(8) A(6) 
42 TAMIM 10 M A SEVERE 10 MONTHS 
JT + 
MM 
SINGLE ELBOW 8 ELBOW 
ON 
DEMAND 
REGULAR 10 8 12 30 11 NE E(5) 
43 PERIVASAM 17 M A SEVERE 1.6 YEARS JOINT SINGLE KNEE 10 KNEE 
ON 
DEMAND 
REGULAR 12 7 9 28 14 1 K(8) 
44 PURUSHOTHAMAN 10 M A SEVERE 1.3YEAR JOINT SINGLE ANKLE 10 ANKLE 
ON 
DEMAND 
REGULAR 12 8 11 31 8 1 A(6) 
45 MANOJ 8 M A SEVERE 1YEAR 
JT + 
MM 
MULTIPLE WRIST 8 WRIST+ ANKLE 
ON 
DEMAND 
REGULAR 11 8 11 30 10 1 W(4)A(6) 
46 RAJKUMAR 6 M A MODERATE 2 YEARS JOINT SINGLE KNEE 6 KNEE 
ON 
DEMAND 
REGULAR 12 7 12 31 8 1 K(6) 
47 MAHAVIR 10 M A SEVERE 1 YEAR 
JT + 
MS 
MULTIPLE ANKLE 14 ANKLE + KNEE 
ON 
DEMAND 
OCCASIONAL 12 6 9 27 18 2 K(6)A(4) 
48 SUNDARESAN 11 M A SEVERE 1.2 YEARS JOINT SINGLE ANKLE 12 ANKLE 
ON 
DEMAND 
OCCASIONAL 12 6 9 27 12 2 A(10) 
49 PRANAV 5 M A SEVERE 1.5 YEARS 
JT + 
MM 
SINGLE ANKLE 6 ANKLE 
ON 
DEMAND 
OCCASIONAL 12 7 11 30 8 0 A(3) 
50 PRITHVI 18 M A MODERATE 2.1 YEARS JOINT SINGLE ANKLE 12 ANKLE 
ON 
DEMAND 
REGULAR 12 8 11 31 11 1 A(5) 
51 VEDHESH 14 M A SEVERE 1.6 YEARS JOINT SINGLE ANKLE 16 ANKLE 
ON 
DEMAND 
OCCASIONAL 12 6 11 29 12 2 A(9) 
52 BHASKARAN 8 M A SEVERE 1YEAR 
JT + 
MM 
MULTIPLE WRIST 8 
WRIST + 
ELBOW 
ON 
DEMAND 
REGULAR 11 8 12 31 10 NE W(4)E(5) 
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53 RAKESH 12 M A SEVERE 1 YEAR 
JT + 
MM 
MULTIPLE KNEE 10 KNEE + ANKLE 
ON 
DEMAND 
OCCASIONAL 12 6 11 29 17 1 K(5)A(4) 
54 SUBRAMANI 14 M A SEVERE 1.7 YEARS JOINT SINGLE ANKLE 12 ANKLE 
ON 
DEMAND 
OCCASIONAL 12 6 9 27 12 1 A(4) 
55 ARUN 13 M A MODERATE 2 YEARS JOINT SINGLE KNEE 6 KNEE 
ON 
DEMAND 
REGULAR 12 7 12 31 5 1 K(4) 
56 KUMARESAN 8 M A SEVERE 11 MONTHS 
JT + 
MM 
SINGLE ELBOW 8 ELBOW 
ON 
DEMAND 
REGULAR 10 8 12 30 8 NE E(4) 
57 MANIKANDAN 15 M A MILD 2.4 YEARS JOINT SINGLE ANKLE 6 ANKLE 
ON 
DEMAND 
OCCASIONAL 12 8 12 32 5 1 A(5) 
58 SURESH 9 M A SEVERE 10 MONTHS JT + 
MS 
MULTIPLE ELBOW 10 ELBOW + 
ANKLE 
ON 
DEMAND 
OCCASIONAL 11 7 11 29 17 1 E(3)A(4) 
59 KHRISNAN 12 M A SEVERE 2 YEARS JOINT SINGLE ANKLE 12 ANKLE ON 
DEMAND 
OCCASIONAL 12 6 10 28 10 1 A(8) 
60 ELIARAJA 10 M A MODERATE 2 YEARS JOINT SINGLE ANKLE 8 ANKLE ON 
DEMAND 
REGULAR 12 7 12 31 4 1 A(4) 
 
*JT-JOINT; MS-MUSCLE; MM-MUCOUS MEMBRANE
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PROFORMA 
 
NAME 
AGE 
SEX 
ADDRESS 
EDUCATIONAL QUALIFICATION 
TYPE OF DISEASE  
SEVERITY 
AGE AT  FIRST HEMARTHROSIS 
FIRST JOINT INVOLVED 
TARGET JOINTS 
CO MORBITIES –  
TYPE OF BLEEDS EXPERIENCED – 
        JOINT/ MUSCLE/ MUCOSAL  
        OTHERS: 
SINGLE/MULTI JOINT DISEASE 
TYPE OF TREATMENT: PROPHYLAXIS/ON-DEMAND 
AVERAGE JOINT BLEED EXPERIENCED PER YEAR 
PHYSIOTHERAPY – DOING REGULARLY/ OCCASIONALLY/ NEVER 
HEMOPHILIA  
HEMOPHILIA JOINT HEALTH SCORE 2.1 
FISH SCORE 
PETTERSON’S X-RAY SCORE 
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FUNCTIONAL INDEPENDENCE SCORE IN HEMOPHILIA (FISH) 
Performance based instrument 
 
 
Patient Name: Patient Code: 
 Today (dd/mm/yyyy):       /        /        . 
 
 
A.Self Care 
1. Eating and grooming 1           2           3           4 
2. Bathing 1           2           3           4 
3. Dressing 1           2           3           4 
B. Transfers 
4. Chair 1           2           3           4 
5. Squatting 1           2           3           4 
C. Locomotion 
6. Walking 1           2           3           4 
7. Stairs (12 - 14 steps) 1           2           3           4 
8. Running 1           2           3           4 
Total Score  
 
 
Scores range from 1 - 4 depending on the degree of independence (see scoring key) 
 
Comments: 
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PETTERSSON’S SCALE OF HEMOPHILIC ARTHROPATHY 
TYPE OF CHANGE FINDING SCORE 
Osteoporosis Absent 0 
Present 1 
Enlarged epiphysis Absent  0 
Present 1 
Irregular subchondral surface Absent 0 
Partially involved 1 
Totally involved 2 
Narrowing of joint space Absent 0 
>1mm 1 
<1mm 2 
Subchondral cyst formation Absent 0 
1 cyst 1 
>1 cyst 2 
Erosion of joint Margins Absent 0 
Present 1 
Gross incongruence of articular bone ends Absent 0 
Slight 1 
Pronounced 2 
Joint deformity (angular and/or displacementbetween 
articulating bones) 
Absent 0 
Slight 1 
Pronounced 2 
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PATIENT CONSENT FORM 
 
STUDY DETAIL : 
STUDY CENTRE : 
PATIENT’S NAME: 
PATIENT’S AGE : 
IDENTIFICATION NUMBER : 
 
I confirm that I have understood the purpose and procedure of the above study. I 
have the opportunity to ask questions and all my questions and doubts have 
been answered to my complete satisfaction. 
I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving reason, without my legal rights being 
affected. 
I understand that the sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory authorities will not 
need my permission to look at my health records, both in respect of the current 
study and any further research that may be conducted in relation to it, even if I 
withdraw from the study I agree to this access. However I understand that my 
identity would not be revealed in any information released to third parties or 
published, unless as required under the law. I agree not to restrict the use of any 
data or results that arise from this study. 
I hereby consent to participate in this study. 
I hereby give permission to undergo complete clinical examination and 
diagnostic tests including haematological, biochemical, radiological tests. 
 
Signature/thumb impression: 
Patient’s name and address:                                              
Place:                              Date: 
Signature of the investigator: 
Name of the investigator:                                                  
Place:                              Date: 
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சுய ஒப்புதல் படிவம் 
ஆய்வு செய்யப்படும் தலைப்பு: இரத்த ஒழுக்கு எலும்பு மூட்டு ந ோய் :  மருத்துவ, 
செயல்போட்டு மற்றும் கதிரியக்க மதிப்பீடு 
 
இடம்:           சபொது மருத்துவத்துவ துலை 
                     அைசு  கீழ்பொக்கம் மருத்துவ கல்லூொி மருத்துவமலை 
                     சென்லை 
 
பங்குசபறுபவொின்  சபயர் : 
பங்குசபறுபவொின்  வயது :                     பங்குசபறுபவொின்  எண் : 
 
மமமை குறிப்பிட்டுள்ள மருத்துவ ஆய்வின் விவைங்கள் எைக்கு 
விளக்கப்பட்டது.  நொன் இவ்வொய்வில் தன்ைிச்லெயொக பங்மகற்கிமறன்.  எந்த 
கொைணத்திைொமைொ எந்த ெட்டெிக்கலுக்கும் உட்படொமல் நொன் இவ்வொய்வில் இருந்து 
விைகிக்சகொள்ளல்ைொம் என்றும் அறிந்து சகொண்மடன். 
இந்த ஆய்வு ெம்பந்தமொகமவொ,  இலத ெொர்ந்து மமலும் ஆய்வு 
மமற்சகொள்ளும்மபொதும் இந்த ஆய்வில்பங்கு சபறும் மருத்துவர் என்னுலடய மருத்துவ 
அறிக்லககலள பொர்ப்பதற்கு என் அனுமதி மதலவயில்லை எை அறிந்து 
சகொள்கிமறன்.  இந்த ஆய்வின் மூைம் கிலடக்கும் தகவலைமயொ, முடிலவமயொ 
பயன்படுத்திக்சகொள்ள மறுக்க மொட்மடன். 
இந்த ஆய்வில் பங்கு சகொள்ள ஒப்புக்சகொள்கிமறன்.   இந்த ஆய்லவ 
மமற்சகொள்ளும் மருத்துவ அணிக்கு உண்லமயுடன் இருப்மபன் என்றும் 
உறுதியளிக்கிமறன். 
 
பங்மகற்பவொின்   லகசயொப்பம்                              ஆய்வொளொின்   லகசயொப்பம் 
 
இடம் : 
மததி : 
